This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The Biopharma industry is always evolving. However, thought leaders in the Biopharma industry offer innovative insights and strategic direction. You're on the right page to find these experts; we’ll discuss Biopharma's top 12 thought leaders, highlighting their unique expertise and what they can teach you. Let’s dive in.
Life science companies are intensifying omics-based research and forming strategicpartnerships to develop effective pharmacological and digital therapies. The convergence of biopharma, digital therapeutics, medical devices, and health technology is enhancing patient care, improving outcomes, and reducing costs.
With 87% of biopharma manufacturers targeting renewable electricity by 2030, CDMOs must align with evolving sustainability regulations and partner expectations. The event also highlighted the industrys commitment to strategicpartnerships, ensuring a sustainable and innovation-driven future for pharmaceutical manufacturing.
Strategicpartnerships with bioinformatics firms and academic institutions will drive next-gen proteomics innovations. of Competitors 80, with revenue greater than $1.0 billion, and Thermo Fisher acquired Olink for $3.1
We organize all of the trending information in your field so you don't have to. Join 61,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
130 
Let's personalize your content